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Aims Metal absorbable scaffolds constitute a conceptually attractive alternative to polymeric scaffolds. Promising 6-month out-
comes of a second-generation drug-eluting absorbable metal scaffold (DREAMS 2G), consisting of an absorbable magne-
sium scaffold backbone, have been reported. We assessed the 12-month safety and performance of this novel device.
Methods
and results
The prospective, international, multi-centre, first-in-man BIOSOLVE-II trial enrolled 123 patients with up to two de novo
lesions with a reference diameter between 2.2 and 3.7 mm. All patients were scheduled for angiographic follow-up at
6 months, and—if subjects consented—at 12 months. Dual antiplatelet therapy was recommended for 6 months.
Quantitative coronary angiography (QCA) parameters remained stable from 6 to 12 months [paired data of 42
patients: in-segment late lumen loss 0.20+ 0.21 mm vs. 0.25+ 0.22 mm, P ¼ 0.117, D 0.05+ 0.21 mm (95%
CI: 20.01;0.12); in-scaffold late lumen loss 0.37+ 0.25 mm vs. 0.39+ 0.27 mm, P ¼ 0.446, D 0.03+ 0.22 (95%
CI: 20.04;0.10), respectively]. Intravascular ultrasound and optical coherence tomography findings corroborated
the QCA results. Target lesion failure occurred in four patients (3.4%), consisting of one death of unknown cause,
one target-vessel myocardial infarction, and two clinically driven target lesion revascularization. No additional event
occurred beyond the 6-month follow-up. During the entire follow-up of 12 months, none of the patients experienced
a definite or probable scaffold thrombosis.
Conclusion The novel drug-eluting metal absorbable scaffold DREAMS 2G showed a continuous favourable safety profile up to
12 months and stable angiographic parameters between 6 and 12 months.
ClinicalTrials.
gov identiﬁer
NCT01960504.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
* Corresponding author. Tel: +49 2131 888 2000, Fax: +49 2131 888 2099, Email: mhaude@lukasneuss.de; michael.haude@uni-due.de
& The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
doi:10.1093/eurheartj/ehw196
See page 2710 for the editorial comment on this article (doi:10.1093/eurheartj/ehw227)
; online publish-ahead-of-print 17 May 2016
European Heart Journal (2016) 37, 2701–2709
Keywords Coronary artery disease † Bioresorbable † Scaffold † DREAMS † Magnesium † PLLA
Introduction
Bioresorbable scaffolds (BRS) have been designed to overcome pro-
blems related to the long-term persistence of metallic stents im-
planted in coronary arteries.1,2 Several randomized controlled
trials (RCTs) comparing polymeric BRS with new-generation
drug-eluting stents (DES) found similar clinical outcomes at
1 year. A recent meta-analysis, though, showed an increased risk
of definite or probable scaffold thrombosis for BRS (1.3% compared
with 0.5%).3 As the true benefit of BRS is expected to ensue later,
long-term data of RCTs are awaited. So far, non-randomized studies
up to 5 years showed promising outcomes.4,5
Absorbable metal scaffolds constitute an attractive alternative
to polymeric BRS, as they conform more to the technique of
percutaneous coronary intervention with DES.6 We assessed a no-
vel second-generation drug-eluting absorbable metal scaffold
(DREAMS 2G), which has been redesigned iteratively by (i) improv-
ing the design of the magnesium backbone of its previous version7,8
and (ii) using the same drug–polymer combination (sirolimus/
poly-L-lactide) as the new-generation biodegradable polymer stent
Orsiro (Biotronik AG, Buelach, Switzerland).9,10 Six-month out-
comes were recently published, showing favourable angiographic
and clinical outcomes with a low rate of target lesion failure (TLF)
and no definite or probable scaffold thrombosis.6 We aimed to
evaluate if those results are sustained at 12 months, a time point
when the magnesium scaffold is expected to be degraded.
Methods
Study design and population
A detailed description of the study has been recently published.6 In brief,
BIOSOLVE-II is a prospective, multi-centre, first-in-man study to evalu-
ate the safety and performance of DREAMS 2G (Biotronik AG, Buelach,
Switzerland). The study is in compliance with the Declaration of Hel-
sinki, Good Clinical Practice, ISO14155, and was approved by the insti-
tutional ethics committees at the participating 13 institutions in Europe,
South America, and Asia. All patients provided written informed
consent.
Eligible patients had stable or unstable angina or documented silent
ischaemia, a maximum of two single de novo lesions in two separate cor-
onary arteries, with a reference vessel diameter between 2.2 and
3.7 mm, a lesion length of ≤21 mm, and a diameter stenosis between
50 and 99%. Exclusion criteria included thrombus in the target vessel,
severe calcification, three-vessel disease, ostial lesion, bifurcation lesion
involving a side branch .2.0 mm in diameter, target lesion located in or
supplied by an arterial or venous bypass graft, and unsuccessful pre-
dilatation. The full list of inclusion and exclusion criteria can be accessed
at clinicaltrials.gov (NCT01960504).
Clinical follow-up was planned at 1, 6, 12, 24, and 36 months. Angio-
graphic follow-up was scheduled at 6 months for all patients, an add-
itional pre-specified imaging follow-up was scheduled at 12 months if
subjects consented. A subgroup of 30 patients underwent intravascular
ultrasound (IVUS), optical coherence tomography (OCT), and
vasomotion testing at 6 months. At this time point, these patients were
also asked to consent for voluntary IVUS, OCT, and vasomotion assess-
ment at 12 months. Only patients without target lesion revascularization
(TLR) were asked for additional 12-month imaging assessment.
Study device
DREAMS 2G is a drug-eluting absorbable metal scaffold system com-
prising of an absorbable magnesium scaffold pre-mounted on a
balloon-expandable delivery system. The scaffold is laser-polished and
its surface is completely coated with bioresorbable poly-L-lactide, which
incorporates sirolimus.6
Endpoints and definitions
The primary endpoint was in-segment late lumen loss (LLL) at 6-month
follow-up. Secondary endpoints at 12 months were TLF, a composite of
cardiac death,11 target-vessel myocardial infarction,12 and clinically
TLR11; scaffold thrombosis11; in-scaffold and in-segment binary resten-
osis; diameter stenosis; and in-scaffold LLL.13
A clinical event committee adjudicated all adverse events, and an in-
dependent core laboratory (Cardialysis B.V., Rotterdam, The Nether-
lands) performed the quantitative coronary angiography (QCA), IVUS,
and OCT analyses. Imaging analysis methods and definitions have been
published previously.6
Figure 1 Patient flow chart. IVUS, intravascular ultrasound;
OCT, optical coherence tomography. aTwo patients who did
not receive an implant were used for calculation of device and pro-
cedural success only. bThirty-four visits were conducted by phone.
cForty-five angiographic assessments of which two were excluded
as they did not have matched projections recorded, one did not
have a 6-month but only 12-month angiography.
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Procedure
The device was available to operators in sizes 2.5 mm × 20 mm,
3.0 mm × 20 mm, or 3.5 mm × 25 mm. Pre-dilatation was mandatory;
post-dilatation was left to the operator’s discretion. Only one study de-
vice per lesion was allowed, although in bailout situations, a second
DREAMS 2G could be used, and, in case of failure, an Orsiro DES.
Dual antiplatelet therapy was recommended for a minimum of 6 months.
The procedural details of vasomotion testing and imaging procedure are
described elsewhere.6
Statistical analysis
The sample size was calculated based on the primary endpoint in-
segment LLL at 6 months and has been previously reported.6 The null
hypothesis was a mean in-segment LLL at 6 months of ≥0.5 mm. An
overall of 121 (101 + 20) subjects were scheduled to be enrolled, as-
suming an expected in-segment LLL mean of 0.45 mm, standard devi-
ation of 0.2 mm, one-sided, significance level of 0.05, and 80% power.
The intention-to-treat analysis population was defined as patients for
whom an investigational scaffold entered the guide catheter following
the diagnostic angiogram. Patients not receiving a study device were in-
cluded in the calculation of procedural success, but excluded from fur-
ther analysis as defined in the study protocol. For serial imaging analysis,
paired data were used.
Descriptive statistical methods were used. Means and standard devia-
tions, medians and interquartile ranges (IQR), and 95% CIs were calcu-
lated as appropriate. For categorical data, absolute and relative
frequencies were calculated and 95% CIs for proportions. P-values
were calculated using paired t-test, Fisher’s exact test, x2 test, and Wil-
coxon signed-rank test, where applicable. All statistical analyses were
performed with SAS (version 9.3).
Role of the funding source
The study was sponsored by Biotronik AG, Buelach, Switzerland. The
sponsor was involved in the design and conduction of the study, data
collection, monitoring, and data analysis.
Results
Between October 2013 and May 2015, 123 subjects were enrolled.
Clinical follow-up at 12 months was 98% (Figure 1). Baseline para-
meters are listed in Table 1. A comparison of baseline parameters
of the angiographic and IVUS/OCT subgroups with serial 6- and
12-month evaluation compared with the overall population is pro-
vided in the Supplementary material online, Table S1. In two lesions,
DREAMS 2G could not be implanted due to insufficient pre-
dilatation; follow-up of these two subjects was consequently not in-
cluded in this analysis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline clinical and lesion characteristics
n 5 123
Mean age, years 65.2+10.3
Male gender 78 (63.4)
Hypertension 101 (82.1)
Hyperlipidaemia 74 (60.2)
Diabetes 36 (29.3)
History of smoking 67 (54.5)
Previous percutaneous coronary interventions 44 (35.8)
CABG 8 (6.5)
History of myocardial infarction 29 (23.6)
Renal failure 4 (3.3)
Congestive heart failure 8 (6.5)
History of stroke or TIA 7 (5.7)
Mean lesion length, mma 12.61+4.53
Mean reference vessel diameter, mm2a 2.68+0.40
AHA/ACC classification type B2/Cb 53 (43.4)
Moderate-to-severe calcification 13 (10.6)
Thrombus 3 (2.4)
Data are shown as mean+ SD or n (%).
AHA/ACC, American Heart Association/American College of Cardiology; CABG,
coronary artery bypass graft; TIA, transient ischaemic attack.
an ¼ 120, in 3 subjects, images were not analysable.
bn ¼ 122, 1 subject not analysable.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Quantitative coronary angiographic analysis (paired data, n 5 42)
Pre-procedure Post-procedure 6 months 12 months
Reference vessel diameter in-segment 2.74+0.35 2.75+0.35 2.60+0.38 2.60+0.41
Reference vessel diameter in-scaffold NA 2.84+0.37 2.66+0.34 2.64+0.44
Minimum lumen diameter in-segment 1.22+0.33 2.25+0.41 2.01+0.38 1.96+0.41
Minimum lumen diameter in-scaffold NA 2.54+0.33 2.14+0.38 2.10+0.41
Acute gain in-segment NA 1.00+0.38 NA NA
Acute gain in-scaffold NA 1.29+0.34 NA NA
Diameter stenosis in-segment 55.2+10.9 18.7+6.8 22.6+9.2 24.7+10.6
Diameter stenosis in-scaffold NA 10.4+6.0 19.6+8.4 20.4+8.6
Binary restenosis in-segment, % NA NA 0 (0) 2 (4.8)
Binary restenosis in-scaffold, % NA NA 0 (0) 0 (0)
Late lumen loss in-segment NA NA 0.20+0.21 0.25+0.22
Late lumen loss in-scaffold NA NA 0.37+0.25 0.39+0.27
Data are shown as mean+ SD or n (%). All measurements are in mm if not otherwise specified. There was no significant difference in outcomes between 6 and 12 months.
NA, not applicable.
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At baseline, 88 (71.5%) patients had stable angina, 17 (13.8%) un-
stable angina, and 18 (14.6%) silent ischaemia. At 12-month follow-
up, 100 (86.2%) patients were symptom-free, 14 (12.1%) had stable
angina (9 CCS class I and 5 CCS class II), 1 (0.9%) had silent ischae-
mia, and none had unstable angina. Fifty-seven patients (48.3%) were
still on dual antiplatelet therapy at 12 months.
Paired QCA data could be obtained in 42 patients from seven
centres at a mean follow-up time of 181+ 17 days and 367+ 17
days for 6- and 12-month assessments, respectively. Paired in-
segment LLL at 6 and 12 months was 0.20+ 0.21 mm (95% CI:
0.13;0.26) and 0.25+ 0.22 mm (95% CI: 0.18;0.32), P ¼ 0.117,
D 0.05+ 0.21 mm (95% CI: 20.01;0.12), and in-scaffold LLL
0.37+ 0.25 mm (95% CI: 0.29;0.45) and 0.39+ 0.27 mm (95%
CI: 0.31;0.48), P ¼ 0.446, D 0.03+0.22 mm (95% CI: 20.04;0.10)
(Table 2, Figure 2). The in-segment and in-scaffold LLL of the overall
population at 6 months were 0.27+0.37 and 0.44+0.36 mm for
the overall population (0.21+0.28 and 0.37+ 0.28 mm in patients
without TLR). There was no statistically significant difference in
baseline characteristics between this subgroup and the overall
patient population.
Serial IVUS and OCT analyses at 6 and 12 months were per-
formed in 11 patients (respective data listings are provided in the
Supplementary material online, Tables S2 and S3). Paired IVUS para-
meters did not differ significantly between 6 and 12 months (median
minimum lumen area of 4.80 vs. 4.69 mm2, P ¼ 0.700), except for
the number of patients with incomplete strut apposition, which
was reduced to zero at 12 months (Supplementary material online,
Table S4; Figure 3). By OCT, the median minimal lumen area de-
creased from 4.58 mm2 at 6 months to 4.19 mm2 at 12 months,
P ¼ 0.032. No intraluminal mass was observed at any time. Figure 4
Figure 2 Cumulative frequency curves for in-segment (A) and in-scaffold (B) late lumen loss. Six- and twelve-month serial analysis of late lumen
loss observed in BIOSOLVE-II compared with BIOSOLVE-I using the precursor device DREAMS first generation.
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shows that at 6 and 12 months, strut-like remnants are only visible
by IVUS but not by OCT.
Serial vasomotion at 6 and 12 months was tested in 14 patients;
thereof 11 (79%) had a change of.3% to the mean lumen diameter
after infusion or injection of acetylcholine (Figure 5). The median
percentage change in mean lumen diameter between pre-and post-
acetylcholine was 22.6% (IQR: 26.4 to 20.6%, mean 25.1+
7.7%) at 6 months and 23.4% (IQR: 29.4 to 3.2%, mean 23.4+
11.0%) at 12 months; the percentage change in mean lumen diam-
eter between post-acetylcholine and nitroglycerine was 3.4%
(IQR: 1.1–9.2%, mean 5.8+ 6.4%) and 6.7% (IQR: 0.0–17.4%,
mean 8.2+ 10.6%), respectively.
Target lesion failure at 12 months was observed in 4/118 patients
(3.4%, 95% CI: 0.9–8.4). No events beyond 6 months occurred.
Specifically, one death (0.8%) of unknown cause on day 134
post-procedure was classified as cardiac death. One target-vessel
myocardial infarction (0.8%) was due to temporary no-reflow after
scaffold implantation. Clinically driven TLR was performed in
two patients (1.7%). One patient died of cancer prior to 6-month
follow-up. No definite or probable scaffold thrombosis was ob-
served. Further details are provided in the Supplementary material
online, Table S5.
Discussion
The main findings of our study are stability of the angiographic and
clinical outcomes of the second-generation device DREAMS 2G be-
tween 6 and 12 months. There was no definite or probable scaffold
thrombosis up to 12 months and no TLF beyond 6 months. These
findings are relevant as 95% of the magnesium scaffold is expected
to be absorbed within 12 months.6 The importance of this time
point for DREAMS 2G is reflected in the recently published Euro-
pean Society of Cardiology–European Association of Percutaneous
Cardiovascular Interventions report on the evaluation on coronary
stents, which states that ‘for bioresorbable stents, critical time
points of follow-up will depend on the pace of biodegradation and
should cover complete resorption’.13
Compared with the first generation, DREAMS 2G has markedly
improved angiographic performance parameters also at 12 months
(in-segment LLL of 0.25+ 0.22 mm vs. 0.39+ 0.33 mm and
in-scaffold LLL of 0.39+0.27 vs. 0.52+0.39 mm).7 There are re-
ports that found a significant relationship between LLL and TLR
even in patients with a LLL of ,0.5mm, but to a lesser extent
than above 0.5 mm.14 In other studies with permanent metallic
stents, an in-segment LLL of ≤0.5 mm has been associated with a
maximal TLR rate of 5%15 and a binary restenosis rate of 5%.16 Fur-
thermore, in an evaluation from 11 RCTs, Pocock et al.17 pointed
out that a 12-month in-segment LLL of ,0.3 mm and in-stent
LLL of ,0.4 mm were associated with very low TLR rates and
that further reductions in LLL are unlikely to reduce clinical re-
stenosis. Correspondingly, a meta-analysis of RCTs showed that
BRS had similar 12-month TLR rates as new-generation DES des-
pite inferior LLL.3 This might also explain the good clinical out-
comes in our series despite a higher LLL. Specifically, compared
with recently established objective performance criteria for cor-
onary stent trials at 9–12 months,13 our series had inferior LLL
[mean in-scaffold LLL of 0.39+ 0.27 mm compared with a median
of 0.18 mm (IQR: 0.13 – 0.25) for new-generation DES], but
comparable clinical outcomes [TLR of 1.7% compared with
2.91% (IQR: 1.67–5.94) for new-generation DES, definitive stent
thrombosis of 0.0% compared with 0.47% (IQR:0.28 to 0.72),
respectively].
Figure 3 Serial changes of intravascular ultrasound parameters in 11 patients. Only a very small neo-intimal hyperplasia area is visible (7 o’clock).
D indicates the difference between follow-ups in mm2 [95% CI].
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One of the encouraging finding is the persisting absence of defin-
ite or probable scaffold thrombosis in this trial and any other trial
with precursor devices of DREAMS 2G, tested in the PROGRESS
or BIOSOLVE-I study.7,8 However, this has to be interpreted with
the caveat that (i) only 123 patients were enrolled, (ii) the results
were not obtained in an all-comers patient population, (iii) rando-
mized controlled data are missing yet, and (iv) dual antiplatelet ther-
apy was recommended for at least 6 months, and nearly half of the
patients were still on dual antiplatelet therapy at 12 months. Still,
these results are promising in the context of a recent meta-analyses
where higher scaffold thrombosis rates (mostly acute and subacute)
were reported for patients treated with polymeric BRS compared
with DES.3,18 Notably, in ABSORB cohort A and B, there was also
no scaffold thrombosis except one iatrogenic scaffold thrombosis
with subsequent myocardial infarction.4,5 Nevertheless, there are
several factors indicating that DREAMS 2G might have a reduced
risk for thrombosis:
(a) In 30 patients assessed up to 6 months6 and 11 up to 12 months,
no intraluminal mass was detected by OCT. At 6 months, no
mal-apposed struts were present, because the scaffold struts
were already embedded into the vessel wall. Furthermore, in
the presence of nearly full absorption of the magnesium scaffold
at 12 months,6 late acquired mal-apposition appears to be im-
possible. This is important since recent observations found
four very late scaffold thrombosis in 171 patients treated with
a polymeric BRS with a longer degradation time compared
with DREAMS 2G. All of those were associated with scaffold
discontinuity, mal-apposed, and/or uncovered scaffold struts
potentially promoting thrombotic events.19
(b) Magnesium has a negatively charged surface promoting
anti-thrombotic properties in vivo.1,20 However, this advantage
might be hypothetical as the scaffold has been shown to be cov-
ered and embedded in the vessel prior to the absorption of the
drug–polymer coating.
Figure 4 Serial angiographic, optical coherence tomography, intravascular ultrasound, and virtual histology of a patient implanted with DREAMS
2G. Matched images show that at 6 months, struts are hardly discernible by optical coherence tomography and the scaffold strut that had covered
the side branch post-procedure (12 o’clock) had disappeared. At 12 months, the vessel surface appears even smoother than at 6 months
(2 o’clock). On intravascular ultrasound, strut remnants are still discernible at follow-up. Assessed by virtual histology, the white colour coding
of the scaffold struts disappears over time demonstrating the absorption process. A–A′, scaffolded segment; P, proximal reference; D, distal
reference.
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(c) DREAMS 2G is laser-polished, leading to a very smooth
surface.6
(d) While struts of absorbable scaffolds are thicker than DES struts,
the strut cross section of DREAMS 2G is rectangular with
rounded edges,1 which might result in better embedding into
the vessel wall.
(e) DREAMS 2G does not require stepwise inflation as required
with polymeric scaffolds,21 which may result in better expan-
sion and apposition.
At 12 months, struts were not discernible by OCT, but IVUS
showed strut-like remnants. In the case example of Figure 4, the
white colour coding of the scaffold struts disappears over time dem-
onstrating the absorption process. This is most likely explained by
the biodegradation of magnesium. Approximately 95% of the mag-
nesium is converted at 12 months.6 In brief, the biodegradation of
magnesium occurs by means of anions and cations exchange, mag-
nesium hydroxide is formed, and in a second step, magnesium hy-
droxide is converted to amorphous calcium phosphate.22,23
Hence, at 12 months, elution of magnesium from the metallic back-
bone is usually completed, and the strut areas are mostly filled by
amorphous calcium phosphate with high water content, which is
not discernible by OCT but to some extent by IVUS. Amorphous
calcium phosphate should not be misinterpreted as calcification
that is associated with an echo shadowing that was not documented
behind the scaffold remnants in IVUS.
Vasodilatation or vasoconstriction .3% was already observed at
6 months, and continued to increase at 12 months. In general, angio-
graphic, IVUS, and OCT parameters remained stable between 6 and
12 months, yet there was a small, but significant decrease in median
minimal lumen area when serially measured by OCT in 11 patients
(20.25 mm2, IQR: 20.64 to 20.09, P ¼ 0.032). Given the very
small number of patients included in the intracoronary imaging sub-
study, these findings should be interpreted with caution. Since
DREAMS 2G was designed to provide a longer scaffolding time
compared with DREAMS 1G, it may be assumed that late lumen en-
largement is postponed and unlikely to be seen as early as after
1 year. Additional longer-term follow-up evaluation is required to
confirm luminal enlargement, as shown for other polymeric scaf-
folds or previous versions of the magnesium scaffold implanted in
the PROGRESS and BIOSOLVE-I studies.5,8,24
Limitations
As with most first-in-man trials, BIOSOLVE-II was not randomized
and included a limited population with simple lesions. Consequently,
comparisons with other devices have to be interpreted with
caution.
The clinical follow-up rate was high, but—attributed to the fact
that it was voluntary per protocol—only a relatively small cohort
was available for serial QCA, IVUS, and OCT assessments. The
demographics of these patients were comparable to those of the
overall study cohort, but nevertheless
(a) the data were only powered for in-segment LLL at 6 month,
(b) eventually, a bias is introduced as symptomatic patients may be
more prone to agree to 12-month imaging assessments than
asymptomatic patients, and
(c) 12-month imaging assessments were not performed in all par-
ticipating centres.
A further limitation is that long-term data are pending to document
lumen enlargement—as seen in BIOSOLVE-I at 3 years.24 Finally, the
Figure 5 Change in vasomotion between 6 and 12 months. Percentage change in mean lumen diameter after acetylcholine and after subsequent
intracoronary injection of nitroglycerine at 6 and 12 months in 14 patients. Each line reflects one patient. The ends of the boxes represent the first
and third quartiles, the band the median, and the crystal the mean. There was no statistical significant difference between 6 and 12 months
(P ¼ 0.808 for acetylcholine and P ¼ 0.626 for nitroglycerine). ACH, acetylcholine; Nitro, nitroglycerine.
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favourable outcomes of BIOSOLVE-II need to be confirmed in more
complex patient and lesion scenarios.
Conclusion
This novel absorbable metal scaffold showed a sustained favourable
safety profile up to 12 months and no increase in LLL between 6 and
12 months in a subgroup of 42 patients. No additional TLF event oc-
curred beyond 6 months. These findings suggest that DREAMS 2G
can be considered as an alternative to current polymeric BRS.
Supplementary material
Supplementary material is available at European Heart Journal online.
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